Christa Dowell
Family · McDaniels, KYNPI 1841509601
Payments from drug & device makers
Across 134 payments — averaging $14.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$885
- Bayer$244
- Novo Nordisk$148
- Lundbeck LLC$103
- GSK$67
- Otsuka America Pharmaceutical, Inc.$65
- plus $419 from 12 others
What the payments were for
- Food & beverage$1,932100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 67 | $885 |
| Bayer | 17 | $244 |
| Novo Nordisk | 10 | $148 |
| Lundbeck LLC | 6 | $103 |
| GSK | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 4 | $65 |
| Amgen | 4 | $54 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 3 | $44 |
| Lilly USA, LLC | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Pfizer | 2 | $34 |
| Novartis | 2 | $34 |
| Alkermes, Inc. | 2 | $32 |
| AstraZeneca | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
How this compares
$1,932 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $127,871 |
| JardianceEmpagliflozin | 125 | $112,139 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $104,903 |
| MounjaroTirzepatide | 61 | $77,243 |
| VraylarCariprazine Hcl | 38 | $62,149 |
| RexultiBrexpiprazole | 36 | $54,294 |
| LinzessLinaclotide | 42 | $40,387 |
| EliquisApixaban | 31 | $36,316 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $35,282 |
| XareltoRivaroxaban | 40 | $33,717 |
| Repatha SureclickEvolocumab | 42 | $28,460 |
| FarxigaDapagliflozin Propanediol | 31 | $24,593 |
| Nurtec OdtRimegepant Sulfate | 16 | $24,395 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $22,867 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $22,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $67 | $137,992194 claims |
| Novo NordiskOzempic | $148 | $127,87199 claims |
| AbbVieVraylar, Linzess | $885 | $102,53680 claims |
| Lilly USA, LLCMounjaro, Trulicity | $42 | $89,38672 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $29 | $64,42191 claims |
| PfizerEliquis, Nurtec Odt | $34 | $60,71147 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $65 | $54,29436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.
Other family in McDaniels
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.